vs

Side-by-side financial comparison of Ford Motor Company (F) and Walgreens Boots Alliance (WBA). Click either name above to swap in a different company.

Ford Motor Company is the larger business by last-quarter revenue ($45.9B vs $39.0B, roughly 1.2× Walgreens Boots Alliance). Walgreens Boots Alliance runs the higher net margin — -0.4% vs -24.1%, a 23.6% gap on every dollar of revenue. On growth, Walgreens Boots Alliance posted the faster year-over-year revenue change (7.2% vs -4.8%). Ford Motor Company produced more free cash flow last quarter ($1.1B vs $336.0M). Over the past eight quarters, Walgreens Boots Alliance's revenue compounded faster (4.9% CAGR vs 3.6%).

The Ford Motor Company is an American multinational automobile manufacturer headquartered in Dearborn, Michigan, United States. It was founded by Henry Ford and incorporated on June 16, 1903. The company sells automobiles and commercial vehicles under the Ford brand, and luxury cars under its Lincoln brand. The company is listed on the New York Stock Exchange under the single-letter ticker symbol F and is controlled by the Ford family.

Walgreens Boots Alliance, Inc. (WBA) was an American multinational holding company headquartered in Deerfield, Illinois. The company was formed on December 31, 2014, after Walgreens bought the 55% stake in Alliance Boots that it did not already own. The total price of the acquisition was $4.9 billion in cash and 144.3 million common shares with fair value of $10.7 billion. Walgreens had previously purchased 45% of the company for $4.0 billion and 83.

F vs WBA — Head-to-Head

Bigger by revenue
F
F
1.2× larger
F
$45.9B
$39.0B
WBA
Growing faster (revenue YoY)
WBA
WBA
+12.1% gap
WBA
7.2%
-4.8%
F
Higher net margin
WBA
WBA
23.6% more per $
WBA
-0.4%
-24.1%
F
More free cash flow
F
F
$764.0M more FCF
F
$1.1B
$336.0M
WBA
Faster 2-yr revenue CAGR
WBA
WBA
Annualised
WBA
4.9%
3.6%
F

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
F
F
WBA
WBA
Revenue
$45.9B
$39.0B
Net Profit
$-11.1B
$-175.0M
Gross Margin
-12.5%
16.7%
Operating Margin
-25.2%
0.1%
Net Margin
-24.1%
-0.4%
Revenue YoY
-4.8%
7.2%
Net Profit YoY
-706.0%
-150.9%
EPS (diluted)
$-2.77
$-0.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
F
F
WBA
WBA
Q4 25
$45.9B
Q3 25
$50.5B
Q2 25
$50.2B
$39.0B
Q1 25
$40.7B
$38.6B
Q4 24
$48.2B
$39.5B
Q3 24
$46.2B
$37.5B
Q2 24
$47.8B
$36.4B
Q1 24
$42.8B
$37.1B
Net Profit
F
F
WBA
WBA
Q4 25
$-11.1B
Q3 25
$2.4B
Q2 25
$-36.0M
$-175.0M
Q1 25
$471.0M
$-2.9B
Q4 24
$1.8B
$-265.0M
Q3 24
$892.0M
$-3.0B
Q2 24
$1.8B
$344.0M
Q1 24
$1.3B
$-5.9B
Gross Margin
F
F
WBA
WBA
Q4 25
-12.5%
Q3 25
14.1%
Q2 25
11.8%
16.7%
Q1 25
13.5%
18.0%
Q4 24
14.3%
17.2%
Q3 24
13.0%
16.7%
Q2 24
15.3%
17.8%
Q1 24
14.7%
19.0%
Operating Margin
F
F
WBA
WBA
Q4 25
-25.2%
Q3 25
3.1%
Q2 25
1.0%
0.1%
Q1 25
0.8%
-14.4%
Q4 24
2.6%
-0.6%
Q3 24
1.9%
-2.6%
Q2 24
3.9%
0.3%
Q1 24
2.9%
-35.5%
Net Margin
F
F
WBA
WBA
Q4 25
-24.1%
Q3 25
4.8%
Q2 25
-0.1%
-0.4%
Q1 25
1.2%
-7.4%
Q4 24
3.8%
-0.7%
Q3 24
1.9%
-8.0%
Q2 24
3.8%
0.9%
Q1 24
3.1%
-15.9%
EPS (diluted)
F
F
WBA
WBA
Q4 25
$-2.77
Q3 25
$0.60
Q2 25
$-0.01
$-0.20
Q1 25
$0.12
$-3.30
Q4 24
$0.45
$-0.31
Q3 24
$0.22
$-3.48
Q2 24
$0.46
$0.40
Q1 24
$0.33
$-6.85

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
F
F
WBA
WBA
Cash + ST InvestmentsLiquidity on hand
$38.5B
$830.0M
Total DebtLower is stronger
$7.4B
Stockholders' EquityBook value
$36.0B
$7.2B
Total Assets
$289.2B
$69.4B
Debt / EquityLower = less leverage
1.03×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
F
F
WBA
WBA
Q4 25
$38.5B
Q3 25
$42.2B
Q2 25
$37.5B
$830.0M
Q1 25
$35.2B
$1.1B
Q4 24
$38.3B
$1.2B
Q3 24
$36.9B
$3.1B
Q2 24
$34.6B
$703.0M
Q1 24
$34.5B
$668.0M
Total Debt
F
F
WBA
WBA
Q4 25
Q3 25
Q2 25
$7.4B
Q1 25
$8.0B
Q4 24
$8.1B
Q3 24
$9.6B
Q2 24
Q1 24
Stockholders' Equity
F
F
WBA
WBA
Q4 25
$36.0B
Q3 25
$47.4B
Q2 25
$45.1B
$7.2B
Q1 25
$44.6B
$7.1B
Q4 24
$44.8B
$9.9B
Q3 24
$44.3B
$10.4B
Q2 24
$43.6B
$13.6B
Q1 24
$42.9B
$13.5B
Total Assets
F
F
WBA
WBA
Q4 25
$289.2B
Q3 25
$301.0B
Q2 25
$292.7B
$69.4B
Q1 25
$284.5B
$70.2B
Q4 24
$285.2B
$78.5B
Q3 24
$287.0B
$81.0B
Q2 24
$276.6B
$83.0B
Q1 24
$274.3B
$84.2B
Debt / Equity
F
F
WBA
WBA
Q4 25
Q3 25
Q2 25
1.03×
Q1 25
1.13×
Q4 24
0.81×
Q3 24
0.92×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
F
F
WBA
WBA
Operating Cash FlowLast quarter
$3.9B
$584.0M
Free Cash FlowOCF − Capex
$1.1B
$336.0M
FCF MarginFCF / Revenue
2.4%
0.9%
Capex IntensityCapex / Revenue
6.1%
0.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$12.5B
$580.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
F
F
WBA
WBA
Q4 25
$3.9B
Q3 25
$7.4B
Q2 25
$6.3B
$584.0M
Q1 25
$3.7B
$-199.0M
Q4 24
$3.0B
$-140.0M
Q3 24
$5.5B
$1.3B
Q2 24
$5.5B
$604.0M
Q1 24
$1.4B
$-637.0M
Free Cash Flow
F
F
WBA
WBA
Q4 25
$1.1B
Q3 25
$5.3B
Q2 25
$4.2B
$336.0M
Q1 25
$1.9B
$-418.0M
Q4 24
$530.0M
$-424.0M
Q3 24
$3.5B
$1.1B
Q2 24
$3.4B
$327.0M
Q1 24
$-709.0M
$-989.0M
FCF Margin
F
F
WBA
WBA
Q4 25
2.4%
Q3 25
10.4%
Q2 25
8.4%
0.9%
Q1 25
4.6%
-1.1%
Q4 24
1.1%
-1.1%
Q3 24
7.6%
2.9%
Q2 24
7.1%
0.9%
Q1 24
-1.7%
-2.7%
Capex Intensity
F
F
WBA
WBA
Q4 25
6.1%
Q3 25
4.2%
Q2 25
4.2%
0.6%
Q1 25
4.5%
0.6%
Q4 24
5.2%
0.7%
Q3 24
4.3%
0.7%
Q2 24
4.4%
0.8%
Q1 24
4.9%
1.0%
Cash Conversion
F
F
WBA
WBA
Q4 25
Q3 25
3.02×
Q2 25
Q1 25
7.81×
Q4 24
1.66×
Q3 24
6.17×
Q2 24
3.01×
1.76×
Q1 24
1.04×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

F
F

Ford Blue$26.2B57%
Ford Pro$14.9B33%
Financingincome$2.1B5%
Ford Model E$1.3B3%
Service And Other Revenue$917.0M2%
Extended Service Contracts$455.0M1%
Leasingincome$79.0M0%
Insuranceincome$44.0M0%

WBA
WBA

Pharmacy$24.4B63%
Retail$6.3B16%
International Reportable Segment$6.2B16%
US Healthcare$2.1B5%

Related Comparisons